CanSino Biologics: Td5cp Vaccine for Adolescents and Adults Accepted for New Drug Review

Stock News

Aug 16

CanSino Biologics Inc (HKEX: 06185) announced that its New Drug Application (NDA) for the adsorbed acellular pertussis (five-component) diphtheria-tetanus-pertussis combined vaccine for individuals aged 6 and older (referred to as Td5cp for adolescents and adults) has been accepted by the National Medical Products Administration of the People's Republic of China (NMPA).

The Td5cp vaccine, designed for adolescents and adults, serves as a booster shot for diphtheria, tetanus, and pertussis. While many developed countries have already incorporated such vaccines into their routine immunization schedules, there is currently no approved booster vaccine for adolescents and adults in the domestic market. Therefore, if the product successfully reaches the market, it will fill a significant gap in the domestic market.

The company's previously approved vaccine for infants, the adsorbed acellular pertussis (three-component) diphtheria-tetanus-pertussis combined vaccine for children under 2 years old (DT3cP), received NDA approval in April 2026. The Td5cp vaccine for adolescents and adults includes two additional pertussis antigen components compared to the infant DT3cP vaccine, making it a five-component pertussis vaccine. Each pertussis antigen can be purified individually and formulated at precise ratios, ensuring batch-to-batch consistency and more stable product quality.

The Td5cp vaccine for adolescents and adults has been granted priority review status by the Center for Drug Evaluation of the NMPA.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1126831454"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126831454\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126831454?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-16 18:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126831454","market":"hk","top_or_hot":-1,"title":"CanSino Biologics: Td5cp Vaccine for Adolescents and Adults Accepted for New Drug Review","media":"Stock News","content":"<p><b>CanSino Biologics Inc</b> (HKEX: 06185) announced that its New Drug Application (NDA) for the adsorbed acellular pertussis (five-component) diphtheria-tetanus-pertussis combined vaccine for individuals aged 6 and older (referred to as Td5cp for adolescents and adults) has been accepted by the National Medical Products Administration of the People's Republic of China (NMPA).<br><br>The Td5cp vaccine, designed for adolescents and adults, serves as a booster shot for diphtheria, tetanus, and pertussis. While many developed countries have already incorporated such vaccines into their routine immunization schedules, there is currently no approved booster vaccine for adolescents and adults in the domestic market. Therefore, if the product successfully reaches the market, it will fill a significant gap in the domestic market.<br><br>The company's previously approved vaccine for infants, the adsorbed acellular pertussis (three-component) diphtheria-tetanus-pertussis combined vaccine for children under 2 years old (DT3cP), received NDA approval in April 2026. The Td5cp vaccine for adolescents and adults includes two additional pertussis antigen components compared to the infant DT3cP vaccine, making it a five-component pertussis vaccine. Each pertussis antigen can be purified individually and formulated at precise ratios, ensuring batch-to-batch consistency and more stable product quality.<br><br>The Td5cp vaccine for adolescents and adults has been granted priority review status by the Center for Drug Evaluation of the NMPA.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CanSino Biologics: Td5cp Vaccine for Adolescents and Adults Accepted for New Drug Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanSino Biologics: Td5cp Vaccine for Adolescents and Adults Accepted for New Drug Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-16 18:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>CanSino Biologics Inc</b> (HKEX: 06185) announced that its New Drug Application (NDA) for the adsorbed acellular pertussis (five-component) diphtheria-tetanus-pertussis combined vaccine for individuals aged 6 and older (referred to as Td5cp for adolescents and adults) has been accepted by the National Medical Products Administration of the People's Republic of China (NMPA).<br><br>The Td5cp vaccine, designed for adolescents and adults, serves as a booster shot for diphtheria, tetanus, and pertussis. While many developed countries have already incorporated such vaccines into their routine immunization schedules, there is currently no approved booster vaccine for adolescents and adults in the domestic market. Therefore, if the product successfully reaches the market, it will fill a significant gap in the domestic market.<br><br>The company's previously approved vaccine for infants, the adsorbed acellular pertussis (three-component) diphtheria-tetanus-pertussis combined vaccine for children under 2 years old (DT3cP), received NDA approval in April 2026. The Td5cp vaccine for adolescents and adults includes two additional pertussis antigen components compared to the infant DT3cP vaccine, making it a five-component pertussis vaccine. Each pertussis antigen can be purified individually and formulated at precise ratios, ensuring batch-to-batch consistency and more stable product quality.<br><br>The Td5cp vaccine for adolescents and adults has been granted priority review status by the Center for Drug Evaluation of the NMPA.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1126831454","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126831454","pubTimestamp":1786875254,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CanSino Biologics Inc (HKEX: 06185) announced that its New Drug Application (NDA) for the adsorbed acellular pertussis (five-component) diphtheria-tetanus-pertussis combined vaccine for individuals...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","BK1161":"生物科技","BK1574":"生物医药B类股","06185":"康希诺生物","IPOS":"Renaissance International IPO ETF"},"translate_title":"康希诺生物：青少年和成人Td5cp疫苗接受新药审评","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"06185":1},"content_text":"CanSino Biologics Inc (HKEX: 06185) announced that its New Drug Application (NDA) for the adsorbed acellular pertussis (five-component) diphtheria-tetanus-pertussis combined vaccine for individuals aged 6 and older (referred to as Td5cp for adolescents and adults) has been accepted by the National Medical Products Administration of the People's Republic of China (NMPA).The Td5cp vaccine, designed for adolescents and adults, serves as a booster shot for diphtheria, tetanus, and pertussis. While many developed countries have already incorporated such vaccines into their routine immunization schedules, there is currently no approved booster vaccine for adolescents and adults in the domestic market. Therefore, if the product successfully reaches the market, it will fill a significant gap in the domestic market.The company's previously approved vaccine for infants, the adsorbed acellular pertussis (three-component) diphtheria-tetanus-pertussis combined vaccine for children under 2 years old (DT3cP), received NDA approval in April 2026. The Td5cp vaccine for adolescents and adults includes two additional pertussis antigen components compared to the infant DT3cP vaccine, making it a five-component pertussis vaccine. Each pertussis antigen can be purified individually and formulated at precise ratios, ensuring batch-to-batch consistency and more stable product quality.The Td5cp vaccine for adolescents and adults has been granted priority review status by the Center for Drug Evaluation of the NMPA.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}